Renalytix uses cookies to improve your experience. We respect your privacy and are committed to protecting your personal data. Read Privacy Notice.
Investors KidneyIntelX

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today


Read More
By |2024-06-21T13:56:44+00:0011.14.23|News|Comments Off on Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024

Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday, November 14, 2023, before market open. The Company will host a corresponding conference call and live


Read More
By |2024-06-21T13:56:45+00:0011.07.23|News|Comments Off on Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14

US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and


Read More
By |2024-06-21T13:56:45+00:0010.06.23|News|Comments Off on US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix

Renalytix Reports Full Year Fiscal 2023 Results

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care,


Read More
By |2024-06-21T13:56:46+00:0009.28.23|News|Comments Off on Renalytix Reports Full Year Fiscal 2023 Results

Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday, September 28, 2023, before market open. The Company will host a corresponding conference call and live


Read More
By |2024-06-21T13:56:46+00:0009.25.23|News|Comments Off on Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28

Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

Doran Brings Significant Diagnostics Sector Experience to Lead the KidneyIntelX Global Sales Effort LONDON and SALT LAKE CITY, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled


Read More
By |2024-06-21T13:56:46+00:0009.07.23|News|Comments Off on Renalytix Appoints Senior Executive Howard Doran as Chief Business Officer

Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc  (LSE: RENX) (NASDAQ:RNLX) announces the launch of its


Read More
By |2024-06-21T13:56:47+00:0008.03.23|News|Comments Off on Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Commercial availability of kidneyintelX.dkd™ expanded to an estimated  4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing to address early-stage kidney disease in region with one of the highest incidence rates for type 2 diabetes globally LONDON and SALT


Read More
By |2024-06-21T13:56:47+00:0007.21.23|News|Comments Off on Renalytix Announces Middle East Distribution Agreement with Vector Pharma

Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

12 Months KidneyIntelX™ in vitro prognostic testing continued to demonstrate clinical actions that lead to improvement in both diabetes (A1C reductions) and kidney health (eGFR slope improvement) in patients with Type 2 Diabetes and Chronic Kidney Disease LONDON and SALT LAKE CITY, July 07, 2023


Read More
By |2024-06-21T13:56:47+00:0007.07.23|News|Comments Off on Late-Breaking KidneyIntelX Evidence Released at 83rd American Diabetes Association Scientific Sessions

Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors

LONDON and SALT LAKE CITY, July 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc  (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces the


Read More
By |2024-06-21T13:56:48+00:0007.03.23|News|Comments Off on Renalytix Appoints Financial Executive Catherine Coste to its Board of Directors
Go to Top